Top Core and Group Health Stories
Merck pays $20 million for cancer drug
By Jack CraverThe university will also be due royalties in the event that the experimental medication becomes a big money-maker.
Core and Group Health
News, insight, and analysis from industry experts to help benefits brokers, consultants and advisors make their way through the tumultuous reformed health care marketplace. Content will help them grow their practices by focusing on a wide range of products, discussing new sales and marketing strategies and highlighting innovative and disruptive brokers who are forging a new path in today's benefits marketplace.